# Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

> **NCT04532294** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 18 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** BGB DXP593
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04532294
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-08
- **Primary completion:** 2021-02-13
- **Final completion:** 2021-02-13
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532294, "Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04532294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*